ArticlePloS one2013
The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Complex cognitive and motivational deficits precede motor dysfunction in the zQ175 (190 CAG repeat) Huntington's disease model.Experimental neurology · 2025Article
- Article
- Scheduled feeding improves sleep in a mouse model of Huntington's disease.bioRxiv : the preprint server for biology · 2024Article
- Dietary fasting and time-restricted eating in Huntington's disease: therapeutic potential and underlying mechanisms.Translational neurodegeneration · 2024Review
- Sex differences in sleep architecture in a mouse model of Huntington's disease.Journal of neuroscience research · 2024Article
- Scheduled feeding improves sleep in a mouse model of Huntington's disease.Frontiers in neuroscience · 2024Article
- Circadian modulation by time-restricted feeding rescues brain pathology and improves memory in mouse models of Alzheimer's disease.Cell metabolism · 2023Article
- Sleep Disorders in Patients with Choreic Syndromes.Current neurology and neuroscience reports · 2023Review
- Sleep and Circadian Rhythm Dysfunction in Animal Models of Huntington's Disease.Journal of Huntington's disease · 2023Review
- Bouts of rest and physical activity in C57BL/6J mice.PloS one · 2023Article
- Sleep Disorders and Circadian Disruption in Huntington's Disease.Journal of Huntington's disease · 2023Review
- A Phenomenological Mouse Circadian Pacemaker Model.Journal of biological rhythms · 2022Article
- Article
- Circadian and ultradian rhythms in normal mice and in a mouse model of Huntington's disease.Chronobiology international · 2022Article
- Dietary ketosis improves circadian dysfunction as well as motor symptoms in the BACHD mouse model of Huntington's disease.Frontiers in nutrition · 2022Article
- Circadian rhythms in neurodegenerative disorders.Nature reviews. Neurology · 2022Review
- Temporal Phenotypic Changes in Huntington's Disease Models for Preclinical Studies.Journal of Huntington's disease · 2022Article
- Impaired Refinement of Kinematic Variability in Huntington Disease Mice on an Automated Home Cage Forelimb Motor Task.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Defining circadian disruption in neurodegenerative disorders.The Journal of clinical investigation · 2021Review
- Systemic manifestation and contribution of peripheral tissues to Huntington's disease pathogenesis.Ageing research reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep and circadian disruptions are commonly reported by patients with neurodegenerative diseases, suggesting these may be an endophenotype of the disorders. Several mouse models of Huntington's disease (HD) that recapitulate the disease progression and motor dysfunction of HD also exhibit sleep and circadian rhythm disruption. Of these, the strongest effects are observed in the transgenic models with multiple copies of mutant huntingtin gene. For developing treatments of the human disease, knock-in (KI) models offer advantages of genetic precision of the insertion and control of mutation copy number. Therefore, we assayed locomotor activity and immobility-defined sleep in a new model of HD with an expansion of the KI repeats (Q175). We found evidence for gene dose- and age-dependent circadian disruption in the behavior of the Q175 line. We did not see evidence for loss of cells or disruption of the molecular oscillator in the master pacemaker, the suprachiasmatic nucleus (SCN). The combination of the precise genetic targeting in the Q175 model and the observed sleep and circadian disruptions make it tractable to study the interaction of the underlying pathology of HD and the mechanisms by which the disruptions occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.